Re: "Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem" by Nervo et al.

B Dear Editor: b Recently, Nervo I et al. i ([1]) presented the results of their retrospective analysis of 36 patients treated with lenvatinib for advanced radioactive iodine (RAI) refractory (RAI-R) differentiated thyroid cancer (DTC) and poorly differentiated thyroid cancer (PDTC) from June 2012 to December 2018. This letter is for supporting the findings of Nervo I et al. i since we also observed this type of AE in our series of 84 RAI-R DTC/PDTC patients who were treated with lenvatinib from February 2012 to September 2018. Our data are comparable with those of Nervo I et al. i and confirm that overall, pulling together the 2 series, GB/BD are present in 16 of 118 (13.5%) of patients treated with lenvatinib. [Extracted from the article]